BCAX · Bicara Therapeutics Inc
United States · RS rating 7 · As of 2026-11-03
| Price | 8.96 USD |
|---|---|
| 1-day change | +13.0% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 4 / 5 / 24 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 40 / 12 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -1.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +70.5% |
| Market cap (USD) | $1.5B |